- Home
- SBS vs RPRX Comparison
SBS vs RPRX Comparison
Compare SBS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBS
- RPRX
- Stock Information
- Founded
- SBS 1954
- RPRX 1996
- Country
- SBS Brazil
- RPRX United States
- Employees
- SBS N/A
- RPRX N/A
- Industry
- SBS Water Supply
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- SBS Utilities
- RPRX Health Care
- Exchange
- SBS Nasdaq
- RPRX Nasdaq
- Market Cap
- SBS 13.7B
- RPRX 13.9B
- IPO Year
- SBS 2002
- RPRX 2020
- Fundamental
- Price
- SBS $21.74
- RPRX $36.45
- Analyst Decision
- SBS
- RPRX Strong Buy
- Analyst Count
- SBS 0
- RPRX 3
- Target Price
- SBS N/A
- RPRX $47.33
- AVG Volume (30 Days)
- SBS 889.0K
- RPRX 4.4M
- Earning Date
- SBS 08-07-2025
- RPRX 08-07-2025
- Dividend Yield
- SBS 2.51%
- RPRX 2.42%
- EPS Growth
- SBS 184.67
- RPRX 37.60
- EPS
- SBS 2.61
- RPRX 2.45
- Revenue
- SBS $6,629,708,013.00
- RPRX $2,263,845,000.00
- Revenue This Year
- SBS N/A
- RPRX $29.35
- Revenue Next Year
- SBS $13.13
- RPRX $7.58
- P/E Ratio
- SBS $8.12
- RPRX $14.83
- Revenue Growth
- SBS 43.80
- RPRX 1.13
- 52 Week Low
- SBS $13.87
- RPRX $24.05
- 52 Week High
- SBS $22.18
- RPRX $36.43
- Technical
- Relative Strength Index (RSI)
- SBS 60.85
- RPRX 64.64
- Support Level
- SBS $21.04
- RPRX $35.01
- Resistance Level
- SBS $22.18
- RPRX $36.33
- Average True Range (ATR)
- SBS 0.39
- RPRX 0.63
- MACD
- SBS 0.08
- RPRX 0.05
- Stochastic Oscillator
- SBS 81.75
- RPRX 90.72
About SBS Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp (Each repstg 250)
Companhia De Saneamento Basico Do Estado De Sao Paulo is engaged in the provision of basic and environmental sanitation services in the Sao Paulo State and supplies treated water and sewage services on a wholesale basis. The company operates in a single segment, which is Sanitation services.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.